Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
14 May 24
10-K
2023 FY
Annual report
1 Apr 24
PRER14C
Preliminary revised information
26 Feb 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
13 Apr 23
NT 10-K
Notice of late annual filing
3 Apr 23
8-K
Changes in Registrant's Certifying Accountant
26 Jan 23
PRE 14A
Preliminary proxy
21 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Entry into a Material Definitive Agreement
21 Jun 22
8-K
Entry into a Material Definitive Agreement
19 May 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
12 Apr 22
NT 10-K
Notice of late annual filing
31 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
8-K/A
Changes in Registrant's Certifying Accountant
10 Nov 21
8-K
Termination of a Material Definitive Agreement
1 Nov 21
8-K
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric
19 Aug 21
10-Q
2021 Q2
Quarterly report
18 Aug 21
NT 10-Q
Notice of late quarterly filing
17 Aug 21
8-K
Changes in Registrant's Certifying Accountant
4 Aug 21
EFFECT
Notice of effectiveness
29 Jun 21
CORRESP
Correspondence with SEC
24 Jun 21
S-1/A
IPO registration (amended)
14 Jun 21
CORRESP
Correspondence with SEC
14 Jun 21
UPLOAD
Letter from SEC
24 May 21
10-Q
2021 Q1
Quarterly report
17 May 21
S-1
IPO registration
7 May 21
10-K
2020 FY
Annual report
26 Mar 21
8-K
Entry into a Material Definitive Agreement
16 Mar 21
10-Q
2020 Q3
Quarterly report
19 Nov 20
NT 10-Q
Notice of late quarterly filing
16 Nov 20
10-Q
2020 Q2
Quarterly report
17 Aug 20
NT 10-Q
Notice of late quarterly filing
13 Aug 20
DEF 14C
Information statement
22 Jul 20
EFFECT
Notice of effectiveness
20 Jul 20
Latest ownership filings